Furthermore, Dox-induced GADD45g knockdown with concurrent JAK2 inhibition led to a partial restoration of tumor burden and a shortened survival, as compared to treatment with ruxolitinib alone (Fig. 10f, g). Here, JAK2 is linked to neoplasm.